Technical Analysis for TH - Theratechnologies Inc.

Grade Last Price % Change Price Change
F 1.810 0.00% 0.000
TH closed unchanged on Friday, April 19, 2024, on 29 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 0.56%
Wide Bands Range Expansion 0.56%
Oversold Stochastic Weakness 0.56%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 19 hours ago
Outside Day about 19 hours ago
Up 2% about 19 hours ago
Up 1% about 20 hours ago
Fell Below Previous Day's Low about 23 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Theratechnologies Inc. Description

Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Drug Medical Specialties IPO Organ Systems Immunology Hiv Infection Rift Antivirals

Is TH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.45
52 Week Low 0.73
Average Volume 27,481
200-Day Moving Average 2.034
50-Day Moving Average 1.960
20-Day Moving Average 1.961
10-Day Moving Average 1.898
Average True Range 0.114
RSI (14) 42.86
ADX 20.28
+DI 16.927
-DI 24.318
Chandelier Exit (Long, 3 ATRs) 1.929
Chandelier Exit (Short, 3 ATRs) 1.971
Upper Bollinger Bands 2.254
Lower Bollinger Band 1.667
Percent B (%b) 0.24
BandWidth 29.962
MACD Line -0.032
MACD Signal Line -0.009
MACD Histogram -0.0227
Fundamentals Value
Market Cap 139.39 Million
Num Shares 77 Million
EPS -0.09
Price-to-Earnings (P/E) Ratio -20.34
Price-to-Sales 2.87
Price-to-Book 21.32
PEG Ratio -199.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.900
Resistance 3 (R3) 1.903 1.877 1.885
Resistance 2 (R2) 1.877 1.854 1.875 1.880
Resistance 1 (R1) 1.843 1.840 1.860 1.840 1.875
Pivot Point 1.817 1.817 1.825 1.815 1.817
Support 1 (S1) 1.783 1.794 1.800 1.780 1.745
Support 2 (S2) 1.757 1.780 1.755 1.740
Support 3 (S3) 1.723 1.757 1.735
Support 4 (S4) 1.720